Peptide Encyclopedia

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein in human gastric juice, studied in preclinical research for tissue repair via the VEGFR2 / angiogenesis pathway.

CJC-1295 is a synthetic long-acting GHRH analogue with an optional albumin-binding (DAC) moiety that extends its half-life to 6–8 days, studied preclinically for growth hormone release.

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nine-amino-acid neuromodulator first isolated from sleeping-rabbit cerebral venous blood in 1977, studied preclinically for sleep and stress responses.

Epithalon is a synthetic tetrapeptide developed in Russia as a short analogue of the pineal peptide epithalamin, studied preclinically for telomerase activity, circadian rhythm, and age-related endpoints.

GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma in 1973 and studied for roles in wound healing and copper transport.

GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist used clinically in Japan as a diagnostic agent for growth hormone deficiency and studied in research as a GH secretagogue.

GHRP-6 is an early-generation synthetic hexapeptide ghrelin receptor agonist that stimulates growth hormone release and, uniquely for this class, also produces a marked increase in appetite via hypothalamic ghrelin circuits.

Ipamorelin is a selective pentapeptide growth hormone secretagogue that stimulates GH release from the pituitary without significantly raising prolactin, ACTH, or cortisol.

Melanotan-2 is a synthetic cyclic heptapeptide analogue of α-MSH that activates melanocortin receptors (MC1R/MC3R/MC4R), studied preclinically for pigmentation and, via MC4R, for sexual-function endpoints.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene, studied preclinically for AMPK signalling, glucose homeostasis, and metabolic adaptation to exercise.

PT-141 (bremelanotide) is an MC4R-preferring melanocortin agonist — the free-acid analogue of melanotan-2 — studied clinically for sexual-function endpoints and approved in the US as Vyleesi for HSDD.

Retatrutide is an investigational triple-agonist peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors, developed by Eli Lilly for obesity and type 2 diabetes.

Semaglutide is a long-acting GLP-1 receptor agonist approved by Health Canada for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

Sermorelin is GRF(1-29)-NH₂, the N-terminal 29-residue fragment of endogenous human GHRH and a pituitary GH secretagogue acting via the GHRH receptor.

TB-500 is a synthetic acetylated heptapeptide corresponding to the active fragment (residues 17–23) of thymosin β4, studied preclinically for actin binding, angiogenesis, and wound repair.

Tesamorelin is a synthetic GHRH analogue that stimulates endogenous growth hormone release, approved for HIV-associated lipodystrophy and studied in research settings for visceral adiposity and cognition.

Thymosin β4 (Tβ4) is a naturally occurring 43-amino-acid actin-sequestering peptide, the full-length parent of the TB-500 research fragment, studied clinically for wound healing, dry-eye disease, and cardiac repair.

Tirzepatide is a dual GLP-1 / GIP receptor co-agonist approved by Health Canada as Mounjaro for type 2 diabetes and under the SURMOUNT programme for obesity.